Role of the MDM2 SNP309 polymorphism in the initiation and early age of onset of nasopharyngeal carcinoma

Molecular Carcinogenesis

Volumn 50, Issue 2, 2011, Pages 73-79

  Sousa, Hugo ^a,b   Pando, Mafalda ^a   Breda, Eduardo ^a   Catarino, Raquel ^a,b   Medeiros, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Epstein Barr virus (EBV); Genetic polymorphism; MDM2; Nasopharyngeal carcinoma; Viral associated neoplasias

Indexed keywords

PROTEIN MDM2; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NASOPHARYNX CARCINOMA; ONSET AGE; PORTUGAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN POLYMORPHISM; RISK;

ADULT; AGE OF ONSET; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PORTUGAL; PROTO-ONCOGENE PROTEINS C-MDM2; RISK; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN HERPESVIRUS 4;

EID: 78651458053     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20689     Document Type: Article

References (40)

1. Breda E, Catarino R, Azevedo I, Fernandes T, Barreira da Costa C, Medeiros R. Characterization of the clinical evolution of nasopharyngeal carcinoma in Portuguese population. Acta Otorrinolaringol Esp 2007;58:191-197.
2. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004;5:423-428.
3. Breda E, Catarino R, Coelho A, Sousa H, Medeiros R. Nasopharyngeal carcinoma study: Introduction and multidisciplinary perspective. Acta Med Port 2008;21:273-284.
4. Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 2005;15:3-15.
5. Amon W, Binne UK, Bryant H, Jenkins PJ, Karstegl CE, Farrell PJ. Lytic cycle gene regulation of Epstein-Barr virus. J Virol 2004;78:13460-13469.
6. Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 2005;15:149-156.
7. Binne UK, Amon W, Farrell PJ. Promoter sequences required for reactivation of Epstein-Barr virus from latency. J Virol 2002;76:10282-10289.
8. Sato Y, Kamura T, Shirata N, et al. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathog 2009;5:e1000530.
9. Sato Y, Shirata N, Kudoh A, et al. Expression of Epstein-Barr virus BZLF1 immediate-early protein induces p53 degradation independent of MDM2, leading to repression of p53-mediated transcription. Virology 2009;388:204-211.
10. Kudoh A, Fujita M, Zhang L, et al. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem 2005;280:8156-8163.
11. Bourdon JC, Laurenzi VD, Melino G, Lane D. p53: 25 years of research and more questions to answer. Cell Death Differ 2003;10:397-399.
12. Zhou G, Zhai Y, Cui Y, et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 2007;13:2627-2633.
13. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005;5:3-8.
14. Atwal GS, Bond GL, Metsuyanim S, et al. Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci USA 2007;104:4524-4529.
15. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002;12:53-59.
16. Qian W, Hu LF, Chen F, et al. Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 1995;31B:328-332.
17. Wu HC, Lu TY, Lee JJ, et al. MDM2 expression in EBV-infected nasopharyngeal carcinoma cells. Lab Invest 2004;84:1547-1556.
18. Renouf B, Hollville E, Pujals A, Tetaud C, Garibal J, Wiels J. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Leukemia 2009;23:1557-1563.
19. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 2009;83:4652-4669.
20. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
21. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: Evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007;16:2717-2723.
22. Sousa H, Santos AM, Catarino R, et al. Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. Eur J Cancer Prev 2006;15:362-366.
23. Catarino RJ, Breda E, Coelho V, et al. Association of the A870G cyclin D1 gene polymorphism with genetic susceptibility to nasopharyngeal carcinoma. Head Neck 2006;28:603-608.
24. Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993;71:2689-2697.
25. Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006;118:1275-1278.
26. Pine SR, Mechanic LE, Ambs S, et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007;99:1401-1409.
27. Adams MJ, Jr., Khoury MJ, James LM. The use of attributable fraction in the design and interpretation of epidemiologic studies. J Clin Epidemiol 1989;42:659-662.
28. Cheung FM, Pang SW, Yau TK, Chow SK, Lo KW. Nasopharyngeal intraepithelial lesion: Latent Epstein-Barr virus infection with malignant potential. Histopathology 2004;45:171-179.
29. Bei JX, Li Y, Jia WH, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010;42:599-603.
30. Eldridge AG, O'Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ 2010;17:4-13.
31. Sousa H, Santos AM, Pinto D, Medeiros R. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med 2007;20:731-741.
32. Wertz IE, Dixit VM. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ 2010;17:14-24.
33. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
34. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010;17:86-92.
35. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: Differential control of p53 fate by Mdm2. Science 2003;302:1972-1975.
36. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-5484.
37. Catarino R, Pereira D, Breda E, et al. Oncogenic virus-associated neoplasia: A role for cyclin D1 genotypes influencing the age of onset of disease? Biochem Biophys Res Commun 2008;370:118-122.
38. Costa S, Pinto D, Pereira D, et al. DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: A study on a Portuguese population. Breast Cancer Res Treat 2007;103:209-217.
39. Costa S, Pinto D, Pereira D, et al. XRCC1 Arg399Gln and RAD51 5'UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients. Breast Cancer Res Treat 2008;109:183-185.
40. Santos AM, Sousa H, Catarino R, et al. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 2005;159:143-147.